Apogenix AG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Apogenix AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011801
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Apogenix AG (Apogenix) is a biopharmaceutical company, developing immuno-oncology medicines for the treatment of cancer and other malignant diseases. Its pipeline drug candidates under clinical development include Asunercept (APG101), a CD95 ligand inhibitor, for the treatment of glioblastoma and myelodysplastic syndromes. Apogenix has also developed the proprietary HERA technology platform for the construction of novel hexavalent (TNFSF) receptor agonists for the treatment of cancer. It also conducts preclinical and clinical studies for various tumor indications. The company works in partnership with other pharmaceutical and biotechnology companies as well as collaborates with leading academic institutions for the preclinical, clinical development and commercialization of its proprietary drug candidates. Apogenix is headquartered Heidelberg, Germany.

Apogenix AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Apogenix AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Apogenix AG, Medical Devices Deals, 2011 to YTD 2017 9
Apogenix AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Apogenix AG, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Apogenix Secures US$9.8 Million In Venture Financing 11
Licensing Agreements 12
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 12
AbbVie Enters into Licensing Agreement with Apogenix 13
Apogenix AG – Key Competitors 14
Apogenix AG – Key Employees 15
Apogenix AG – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
09/26/2016: First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan 17
Sep 13, 2017: CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer 18
Mar 20, 2017: Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR) 19
02/16/2016: Apogenix Receives EUR3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101 21
01/07/2016: Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan 22
Product Approvals 23
Jul 26, 2016: CANbridge CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan 23
Apr 07, 2016: CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma 24
Clinical Trials 25
Nov 03, 2016: Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition 25
Jun 15, 2016: Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101 26
Mar 24, 2016: Preclinical Efficacy Data of Apogenix’ APG101 in Myelodysplastic Syndromes Published in Oncotarget 27
Jan 07, 2016: CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Apogenix AG, Pharmaceuticals & Healthcare, Key Facts 2
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Apogenix AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Apogenix AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Apogenix AG, Deals By Therapy Area, 2011 to YTD 2017 8
Apogenix AG, Medical Devices Deals, 2011 to YTD 2017 9
Apogenix AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Apogenix Secures US$9.8 Million In Venture Financing 11
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 12
AbbVie Enters into Licensing Agreement with Apogenix 13
Apogenix AG, Key Competitors 14
Apogenix AG, Key Employees 15

★海外企業調査レポート[Apogenix AG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Edison SpA (EDNR):石油・ガス:M&Aディール及び事業提携情報
    Summary Edison SpA (Edison), a subsidiary of Electricite de France S.A., is an energy company that explores, produces, develops and sells natural gas and crude oil in the Mediterranean Basin. The company generates and sells electricity; and develops, stores, transports and sells gas in Italy. Edison …
  • Norwegian Energy Company ASA (NOR):企業の財務・戦略的SWOT分析
    Summary Norwegian Energy Company ASA (Noreco) is an oil and gas company that offers exploration and development services. The company explores, produces and develops oil, gas, and natural gas liquids deposit properties. It operates through ongoing and planned exploration wells such as PL616 Haribo a …
  • Bright Horizons Family Solutions LLC (BFAM):企業の財務・戦略的SWOT分析
    Summary Bright Horizons Family Solutions LLC (Bright Horizons), subsidiary of Bright Horizons Capital Corp, is a provider of educational advisory services and child care services. It offers curriculum and programs including early education and preschool, back-up child and adult care programs, infant …
  • Venn Life Sciences Holdings Plc (VENN):企業の財務・戦略的SWOT分析
    Summary Venn Life Sciences Holdings Plc (Venn Life Sciences), formerly Armscote Investment Company Plc is a contract research organization that offers drug development, clinical trial management and resourcing solutions. The organization offers drug development services such as clinical pharmacology …
  • Toshiba America Electronic Components, Inc.:企業の戦略的SWOT分析
    Toshiba America Electronic Components, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • ScanSource, Inc. (SCSC):企業の財務・戦略的SWOT分析
    ScanSource, Inc. (SCSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Northrop Grumman Technical Services Inc.:企業の戦略・SWOT・財務分析
    Northrop Grumman Technical Services Inc. - Strategy, SWOT and Corporate Finance Report Summary Northrop Grumman Technical Services Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Selecta Biosciences Inc (SELB):企業の財務・戦略的SWOT分析
    Summary Selecta Biosciences Inc (Selecta Biosciences) is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company’s pipeline products include SEL-212, SEL-403, SEL-302 and SEL-302. It utilizes synthetic vaccine particle (S …
  • Rothschild Bank AG:企業の戦略・SWOT・財務情報
    Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • CryoPort Inc (CYRX):企業の財務・戦略的SWOT分析
    CryoPort Inc (CYRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • NOF Corp (4403):企業の財務・戦略的SWOT分析
    NOF Corp (4403) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Patrys Ltd (PAB):企業の財務・戦略的SWOT分析
    Summary Patrys Ltd (Patrys) is a therapeutic antibody development company focused on IgM antibodies and IgG antibody fragments in the field of oncology. The company's pipeline products include PAT-SC an immunoglobulin M type antibody used for the treatment of gastric cancer PAT-SM is a fully human m …
  • Seven & i Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    Seven & i Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven & i Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Oil and Natural Gas Corporation Limited:戦略・SWOT・企業財務分析
    Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • vTv Therapeutics Inc (VTVT)-製薬・医療分野:企業M&A・提携分析
    Summary vTv Therapeutics Inc (vTv), formerly TransTech Inc is a clinical stage pharmaceutical company that discovers, develops and commercializes small molecule drug candidates. The company’s pipeline products include azeliragon, TTP399, TTP273, HPP593, HPP737, HPP971 and hexokinase II inhibitors. I …
  • Nisshinbo Holdings Inc (3105):企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Volta River Authority:企業の戦略的SWOT分析
    Volta River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • BioInvent International AB (BINV):製薬・医療:M&Aディール及び事業提携情報
    Summary BioInvent International AB (BioInvent) focuses on the discovery and development of antibody drugs for the treatment of cancer. The company uses n-CoDeR, its inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and ident …
  • Miracor Medical Systems GmbH:製品パイプライン分析
    Summary Miracor Medical Systems GmbH (Miracor Medical) is a medical device company that develops and commercializes pressure-controlled intermittent coronary sinus occlusions. The company offers products for continuous monitoring of coronary sinus pressure dynamics. It offers impulse console and imp …
  • Western Power Distribution Plc:企業の戦略的SWOT分析
    Western Power Distribution Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆